Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism

Figure 3 Effect of saroglitazar on plasma ethanol and acetate levels in the therapeutic study design. Mice received saroglitazar or vehicle during a 4-week ethanolfeeding protocol. Blood samples were collected 2 hours after the ethanol binge to determine plasma ethanol and acetate levels. A: It shows plasma ethanol concentrations; B: It shows plasma acetate levels. Data are presented as mean ± SEM (n = 8 for normal control and n = 9 disease control and treatments). Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s multiple comparison test. ^bP < 0.01, ^cP < 0.001 vs disease control group. PO: Orally; OD: Once daily; BID: Twice daily; UDCA: Ursodeoxycholic acid.